Bird Rock Bio Reports Encouraging Data on Inexpensive RA Treatment

Bird Rock Bio, a San Diego-China biopharma, reported positive data from two clinical studies of gerilimzumab, Bird Rock's rheumatoid arthritis drug candidate. At a very low dosage level, gerilimzumab, a novel anti-IL-6 cytokine antibody, was safe and achieved target pharmacokinetic levels. Bird Rock envisions an every-eight-weeks treatment regimen for the drug and an annual drug cost of $2,000. That compares to an every-two-weeks injection and $30,000 for current treatments. In 2013, Bird Rock, then known as RuiYi Pharma, partnered gerilimzumab with China's Genor Biopharma for IND enablement, manufacturing process development and China commercialization. More details....

Share this with colleagues: